SCHEMBL3244907

SCHEMBL3244907

CCOC(=O)c1oc(C(C)(C)C)cc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 4/20 0.44
AHR P35869 1/20 0.44
POLB P06746 1/20 0.43
ALDH1A1 P00352 8/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.42
L3MBTL1 Q9Y468 4/20 0.41
HSD17B10 Q99714 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23462010 0.83 MAPK1 (0.67) MAPK1MEN1KMT2APOLBALDH1A1
SCHEMBL10265347 0.78 KDM4E (0.50) MAPK1MEN1KMT2AKDM4EAHR
SCHEMBL3113960 0.74 MAPK1 (0.68) MAPK1KMT2AKDM4EALDH1A1LMNA
SCHEMBL13912297 0.73 SLC9A1 (0.54) MEN1KMT2AKDM4EAHRALDH1A1
SCHEMBL5548523 0.71 KDM4E (0.50) MAPK1MEN1KMT2AKDM4EAHR
SCHEMBL11235585 0.69 CA12 (0.53) MAPK1ALDH1A1LMNAHSD17B10CA12
SCHEMBL9826102 0.68 CA12 (0.51) KDM4EAHRALDH1A1L3MBTL1CA12
SCHEMBL31688015 0.68 GRM6 (0.53) MEN1KMT2AKDM4EAHRPOLB
SCHEMBL352509 0.68 MAPK1 (0.49) MAPK1MEN1KMT2APOLBALDH1A1
SCHEMBL1980103 0.68 MAPK1 (0.49) MAPK1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160371-A1 INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS RANGES GERALD 2010-06-24 US disclosed
US-20100160371-A1 INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS RANGES GERALD 2010-06-24 US disclosed
EP-1019040-B1 ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES BAYER AG (US) 2004-09-29 EP disclosed
US-20020103253-A1 Inhibition of p38 kinase activity by aryl ureas BAYER CORPORATION (US) 2002-08-01 US disclosed
US-6344476-B1 Inhibition of p38 kinase activity by aryl ureas BAYER CORPORATION 2002-02-05 US disclosed
EP-1019040-A4 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS BAYER AG (US) 2000-10-04 EP disclosed
EP-1019040-A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS Bayer Corporation (US) 2000-07-19 EP disclosed
WO-1998052558-A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS BAYER CORPORATION (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103253-A1 Inhibition of p38 kinase activity by aryl ureas MAPK1, MAP3K1, MAP3K7 MAPK1 1/4885MEN1 4239/4885KMT2A 2738/4885
US-20100160371-A1 INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS MAPK1, MAP3K1, MAP3K7 MAPK1 1/4885MEN1 4239/4885KMT2A 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.